{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:50:02Z","timestamp":1788997802671,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patients with prediabetes are at higher risk of developing type 2 diabetes. While intensive lifestyle modification is the primary approach to delaying diabetes, metformin has been shown to be effective, especially among patients younger than 60 years and obese (body mass index (BMI) &amp;gt; 35 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), patients with fasting blood glucose \u2265 6.1 mmol\/L or HbA1c \u2265 6%, and women with history of gestational diabetes. Thus, metformin is now recommended as an option for diabetes prevention by the American Diabetes Association (ADA). The use of metformin among patients with prediabetes in Saudi Arabia and their adherence to the guideline's recommendation for the prevention of type 2 diabetes is unknown. This study aimed to identify the prevalence of metformin use among prediabetes patients overall and patients who are more likely to benefit from metformin use per the ADA guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted encompassing data from three tertiary care hospitals between January 2015 and June 2019. All patients aged 20 to 70 years with prediabetes (HbA1c of 5.7\u20136.4%) were included, while patients with an established diagnosis of diabetes, creatinine clearance &amp;lt;45 ml\/min, using antihyperglycemic medications other than metformin, or on metformin for other indications were excluded. Prediabetes patients who are most likely to benefit from metformin for type 2 diabetes prevention are those younger than 60 years with a BMI \u2265 35 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , patients with fasting blood glucose \u2265 6.1 mmol\/L or HbA1c \u2265 6%, and women with history of gestational diabetes. This study examined the prevalence of metformin use among all patients with prediabetes, as well as patients who would be more likely to benefit from metformin use per the ADA guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 251 patients were included in this study; 52.2% were female, with a mean age of 47.0 (11.9) years and BMI of 32.3 (6.5) kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and the median HbA1c at baseline was 5.8% (5.7\u20136.0). Among the overall sample, 18 patients (7.2%) received metformin for the prevention of type 2 diabetes, 14 of those were from the groups that are more likely to benefit from metformin use per the ADA guidelines (9.9%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among individuals with prediabetes in Saudi Arabia, metformin use was very low despite the evidence supporting its safety, convenience, and efficacy. Healthcare providers seemed hesitant to medicalize prediabetes; furthermore, the low use of metformin suggests the existence of several barriers that need to be identified and resolved. Increasing providers' knowledge and awareness regarding screening and management of prediabetes is highly encouraged.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2022.989072","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T06:59:26Z","timestamp":1662620366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia"],"prefix":"10.3389","volume":"10","author":[{"given":"Osamah M.","family":"Alfayez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanoud A.","family":"Alsallum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan F.","family":"Aljabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal S.","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Al-Azzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohoud S.","family":"Almalki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed S.","family":"Al Yami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.2337\/dc22-S003","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/1471-2458-10-653","article-title":"Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? a systematic review and meta-analysis","volume":"10","author":"Cardona-Morrell","year":"2010","journal-title":"BMC Public Health."},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1377\/hlthaff.2011.1009","article-title":"How effective were lifestyle interventions in real-world settings that were modeled on the diabetes prevention program?","volume":"31","author":"Ali","year":"2012","journal-title":"Health Aff (Millwood)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3122\/jabfm.2016.02.150252","article-title":"Prediabetes diagnosis and treatment in primary care","volume":"29","author":"Mainous","year":"2016","journal-title":"J Am Board Fam Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3122\/jabfm.2016.06.160138","article-title":"Prediabetes screening and treatment in diabetes prevention: the impact of physician attitudes","volume":"29","author":"Mainous","year":"2016","journal-title":"J Am Board Fam Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2337\/dc13-1223","article-title":"Novel use and utility of integrated electronic health records to assess rates of prediabetes recognition and treatment: brief report from an integrated electronic health records pilot study","volume":"37","author":"Schmittdiel","year":"2014","journal-title":"Diabetes Care."},{"key":"B9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/M14-1773","article-title":"Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study","volume":"162","author":"Moin","year":"2015","journal-title":"Ann Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.joim.2022.04.001","article-title":"Remission of type 2 diabetes depends on prompt comprehensive lifestyle changes upon diagnosis: How can this \u201cRoad to Damascus\u201d experience be supported?","volume":"20","author":"Koufakis","year":"2022","journal-title":"J Integr Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5144\/0256-4947.2014.465","article-title":"The Saudi abnormal glucose metabolism and diabetes impact study (SAUDI-DM)","volume":"34","author":"Al-Rubeaan","year":"2014","journal-title":"Ann Saudi Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0152559","DOI":"10.1371\/journal.pone.0152559","article-title":"The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia: a community-based survey","volume":"11","author":"Bahijri","year":"2016","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2194604","DOI":"10.1155\/2018\/2194604","article-title":"Prevalence of prediabetes, diabetes, and its associated risk factors among males in Saudi Arabia: a population-based survey","volume":"2018","author":"Aldossari","year":"2018","journal-title":"J Diabetes Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2230-8229.108174","article-title":"Economic costs of diabetes in Saudi Arabia","volume":"20","author":"Alhowaish","year":"2013","journal-title":"J Family Community Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc22-Sint","volume":"45","author":"Association","year":"2021","journal-title":"Introduction: Standards of Medical Care in Diabetes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2337\/dc08-S012","volume":"31","author":"Association","year":"2008","journal-title":"Standards of Medical Care in Diabetes"},{"key":"B17","first-page":"363","article-title":"Treating prediabetes with metformin: systematic review and meta-analysis","volume":"55","author":"Lily","year":"2009","journal-title":"Can Fam Physician."},{"key":"B18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.amepre.2018.04.038","article-title":"Review of metformin use for type 2 diabetes prevention","volume":"55","author":"Moin","year":"2018","journal-title":"Am J Prev Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1007\/s11606-017-4103-1","article-title":"Survey of primary care providers' knowledge of screening for, diagnosing and managing prediabetes","volume":"32","author":"Tseng","year":"2017","journal-title":"J Gen Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e21475","DOI":"10.7759\/cureus.21475","article-title":"Survey of primary care physicians' screening and treatment practices for prediabetes in saudi Arabia","volume":"14","author":"Aljehani","year":"2022","journal-title":"Cureus."},{"key":"B22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2337\/ds18-0020","article-title":"Metformin and type 2 diabetes prevention","volume":"31","author":"Aroda","year":"2018","journal-title":"Diabetes Spectrum."},{"key":"B23","unstructured":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2337\/dc20-1675","article-title":"Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF","volume":"44","author":"Inzucchi","year":"2020","journal-title":"Diabetes Care."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.989072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T06:59:31Z","timestamp":1662620371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.989072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":25,"alternative-id":["10.3389\/fpubh.2022.989072"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.989072","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"989072"}}